Request Discount

Cardiac Biomarkers Market (Type - Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Other Types; Location of Testing - Point of Care Testing, and Laboratory Testing; Applications - Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : August, 2019

  • Rep Id : HC0643

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Cardiac Biomarkers Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Cardiac Biomarkers Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Cardiac Biomarkers Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on cardiac biomarkers market provides an in-depth analysis of segments and sub-segments in the global as well as regional cardiac biomarkers market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional cardiac biomarkers market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global cardiac biomarkers market. According to the report, the global cardiac biomarkers market is projected to grow at a CAGR of 10.2% over the forecast period of 2019-2025.


Market Insight

Diagnostic technologies play a vital role in improving the effectiveness of disease management decisions and more efficient utilization of healthcare resources. The development of sensitive and specific markers such as creatine kinase muscles brain (CK-MB), myoglobin, high sensitivity CRP are seen as key to achieving excellence in cardiac care. Circulating biomarkers are key to risk assessment, diagnosis, prognosis, and disease management in cardiovascular disease (CVD). Currently, the two best-established markers in CV disease are the B type cardiac natriuretic peptides and cardiac troponin. These reflect myocyte load and injury and have established roles in the management of heart failure and acute coronary syndromes.


The rise in the number of patients suffering from acute coronary syndrome (ACS) across the globe is the major driving factor for the cardiac biomarkers market. Furthermore, factors such as rapidly increasing geriatric population and development and advancement in cardiac biomarkers are other driving factors for the market growth. Cardiac markers are also used in the diagnosis and risk stratification of patients with chest pain. Rising funding from public or private organizations for research on cardiac biomarkers is fueling the growth of the market. However, technical problems related to sample collection and storage is restraining the growth of the cardiac biomarkers market. Moreover, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is anticipated to provide growth opportunities to the market players.


Geographically, North America dominates the global cardiac biomarkers market owing to the rising patient population suffering from cardiovascular diseases such as angina pectoris, myocardial infraction, etc. Lack of physical activity and unhealthy diet of peoples are other driving factors for the cardiac biomarkers market in the North America region. Asia-Pacific is the fastest-growing region owing to the modernization, increasing disposable incomes and growing affordability for the advanced cardiac treatments.

Global Cardiac Biomarkers Market


Segment Covered

The report on global cardiac biomarkers market covers segments such as type, location of testing, and applications. On the basis of type, the sub-markets include myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and other types. On the basis of location of testing, the sub-markets include point of care testing, and laboratory testing. On the basis of applications, the sub-markets include myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and other applications.


Companies Profiled:

The report provides profiles of the companies in the market such as Beckman Coulter, Inc., Roche Diagnostics Limited, Abbott Laboratories, bioMérieux SA, Johnson and Johnson, Olympus Corporation, Siemens Healthcare GmbH, Tosoh Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of cardiac biomarkers market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount